Evidence analysisNovember 14, 2026Evidence

EMEA-000810-PIP01-09

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.

Evidence Dossier: Paediatric Investigation Plan for Grass, Rye, and Birch Pollen Extracts

What is established

The European Medicines Agency (EMA) oversees the approval and regulation of paediatric investigation plans (PIPs) related to medicinal products used in children. These plans are designed to ensure that medicines intended for paediatric use are appropriately studied in this population to establish safety and efficacy. One such plan, decision number P/218/2010 (PIP number EMEA-000810-PIP01-09), pertains to allergy treatments involving extracts of grass pollen, rye pollen, and birch pollen, specifically for conditions including allergic rhinitis and rhino-conjunctivitis.

This PIP concerns pharmaceutical forms classified as suspensions for subcutaneous injection and was agreed upon by the EMA on 29 October 2010. The marketing authorization holder involved is Allergy Therapeutics (UK) Ltd. The EMA’s decision documents and supporting materials indicate that this plan had granted certain waivers and deferrals related to paediatric studies.

What the source claims

The EMA source documents, specifically those dated in 2010 and more recently in November 2026, provide the following claims and decisions:

  • An agreed paediatric investigation plan exists for the combined pollen extracts targeting pneumology-allergology indications, particularly allergic rhinitis and rhino-conjunctivitis.
  • The plan includes a deferral, meaning that the obligation to complete paediatric studies was delayed to a later timeframe rather than waived entirely.
  • A waiver was granted for certain paediatric subsets—most likely where it was judged studies were not necessary or feasible, though the specific scope is detailed only in EMA documentation.
  • In November 2026, a notification of discontinuation was published, signaling that the paediatric development program originally defined under this PIP had been stopped.

Allergy Therapeutics (UK) Ltd remains the contact point for enquiries related to this matter at the time of the latest update.

What may be missing from the usual framing

The publicly accessible EMA pages and documents provide regulatory decisions and procedural updates but often omit detailed rationales for waivers, deferrals, or the discontinuation. The following points are frequently underreported or omitted:

  • Scientific rationale: Little detailed explanation is made available explaining why specific paediatric subgroups were waived or why deferrals were granted beyond procedural formalities.
  • Outcome and results: There is no readily accessible public data on the results from any paediatric studies conducted under this plan, including any findings on safety, efficacy, dosing, or adverse effects.
  • Patient and clinician perspectives: The documentation lacks insights from paediatric patients, families, or prescribing clinicians about the impact or perceived benefits of these pollen extract therapies in children.
  • Commercial influences: While Allergy Therapeutics is identified as the sponsor, the role of commercial incentives or strategic decisions affecting study discontinuation are not openly discussed.

Competing evidence or uncertainty

The publicly available information does not provide a comprehensive view of all scientific, clinical, or regulatory factors that may have influenced the PIP’s evolution. Specific areas of uncertainty include:

  • The reasons behind the paediatric development discontinuation announced in late 2026 are not clearly described. Potential factors could involve difficulties in study execution, negative results, commercial decisions, or changes in regulatory requirements.
  • The scope of the waivers and deferrals granted—whether they pertain to certain age groups, indications, or study designs—is only broadly outlined, making it difficult to assess the completeness of the paediatric evaluation.
  • Alternative allergy treatments for children and their regulatory statuses may differ, complicating comparisons or contextual understanding of this PIP’s importance.
  • There is insufficient evidence publicly to confirm whether this paediatric investigation plan met current best practices for paediatric drug development, such as patient-centered outcomes or adaptive trial methodologies.

Why it matters

The development and approval of medicines for children, especially in allergy treatment, is a critical area of public health. Allergic rhinitis and rhino-conjunctivitis can significantly impact quality of life, school attendance, and long-term respiratory health. Ensuring that medications are properly studied in children is essential to provide age-appropriate formulations, dosing, and safety profiles.

Decisions by regulators like the EMA on PIPs influence which medicines reach paediatric markets, how they are labelled, and how healthcare providers approach treatment. Discontinuation of a paediatric development program may delay or deny beneficial treatments for children or result in off-label use without strong evidence.

Finally, transparency about the process, results, and reasons for changes in such PIPs contributes to public trust, informed clinical practice, and accountability of pharmaceutical developers and regulators.

What to verify next

  • Access the full EMA documentation linked in the public source to review exact terms, waivers, deferrals, and rationale stated in the original paediatric investigation plan and subsequent updates.
  • Seek clinical trial registries or publications related to the paediatric studies under this PIP to evaluate completed, ongoing, or terminated research outcomes.
  • Investigate statements or reports from Allergy Therapeutics (UK) Ltd that address the discontinuation or current status of the pollen extract formulations for paediatric use.
  • Review independent clinical guidelines and allergy specialist opinions concerning paediatric treatment options for allergic rhinitis and rhino-conjunctivitis, including safety data on pollen extracts.
  • Consider regulatory trends or changes between 2010 and 2026 that may have impacted requirements for paediatric allergy medication development within the EU.

Readers interested in this topic should consult the original EMA source page and linked documentation for comprehensive and authoritative information.

Source & verification

Primary source: What's new · November 13, 2026

Read the original source

FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.

Continue reading

EudraGMDP database

What is established The EudraGMDP database is an established European Union (EU) information system managed by the European Medicines Agency (EMA). It serves as…